Concord Biotech Ltd. (IN:CONCORDBIO)
:CONCORDBIO
Want to see IN:CONCORDBIO full AI Analyst Report?
Top Page
Concord Biotech Ltd.
(CONCORDBIO)
Select Model
Select Model
Rating:66Neutral
Price Target:
₹1,097.00
▼(-18.05% Downside)
Action:ReiteratedDate:02/07/26
The score is driven primarily by strong financial performance (healthy profitability and a low-leverage balance sheet). This is offset by weak technicals (below key moving averages and negative MACD) and a relatively high P/E with only a modest dividend yield.
Positive Factors
Low financial leverage
A low debt-to-equity profile and high equity ratio reduce solvency risk and preserve financial flexibility over time. This durability supports recurring capital spending, R&D and capacity builds without reliance on expensive external financing, improving resilience in downturns.
Negative Factors
Inconsistent free cash flow growth
Fluctuating free cash flow growth can constrain the firm's ability to sustainably fund expansions, acquisitions or higher R&D intensity. Over months to years this variability forces conservative capital allocation, may delay scale investments, and increases sensitivity to operating shocks.
Read all positive and negative factors
Positive Factors
Negative Factors
Low financial leverage
A low debt-to-equity profile and high equity ratio reduce solvency risk and preserve financial flexibility over time. This durability supports recurring capital spending, R&D and capacity builds without reliance on expensive external financing, improving resilience in downturns.
Read all positive factors
Concord Biotech Ltd. (CONCORDBIO) vs. iShares MSCI India ETF (INDA)
Market Cap
₹106.27B
Dividend Yield0.8%
Average Volume (3M)12.81K
Price to Earnings (P/E)54.6
Beta (1Y)1.00
Revenue Growth6.38%
EPS Growth-4.22%
CountryIN
Employees1,377
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)6.30
Shares Outstanding104,616,200
10 Day Avg. Volume31,605
30 Day Avg. Volume12,808
Financial Highlights & Ratios
PEG Ratio2.27
Price to Book (P/B)9.60
Price to Sales (P/S)14.50
P/FCF Ratio127.69
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)37.79
Revenue Forecast (FY)₹14.24B
Concord Biotech Ltd. Business Overview & Revenue Model
Company Description
Concord Biotech Limited, a biopharma company, engages in the research and development, manufacturing, marketing, and sale of pharmaceutical products in India and internationally. It provides fermentation based active pharmaceutical ingredients in ...
How the Company Makes Money
Concord Biotech primarily makes money by manufacturing and selling pharmaceutical APIs, with a significant portion coming from fermentation-based APIs that are typically higher-complexity products requiring specialized process development and larg...
Concord Biotech Ltd. Financial Statement Overview
Summary
Income Statement
85
Very Positive
Balance Sheet
88
Very Positive
Cash Flow
78
Positive
| Breakdown | TTM | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 11.25B | 12.00B | 10.17B | 8.53B | 7.13B | 6.17B |
| Gross Profit | 7.51B | 7.68B | 6.67B | 6.61B | 5.41B | 5.00B |
| EBITDA | 4.56B | 5.13B | 4.39B | 3.53B | 2.78B | 3.29B |
| Net Income | 3.23B | 3.72B | 3.08B | 2.40B | 1.75B | 2.35B |
Balance Sheet | ||||||
| Total Assets | 20.23B | 20.34B | 17.01B | 15.14B | 13.13B | 11.83B |
| Cash, Cash Equivalents and Short-Term Investments | 3.81B | 3.18B | 2.86B | 1.81B | 1.62B | 2.01B |
| Total Debt | 16.07M | 29.69M | 97.38M | 315.47M | 624.93M | 892.83M |
| Total Liabilities | 1.96B | 2.22B | 1.74B | 2.24B | 2.10B | 1.83B |
| Stockholders Equity | 18.27B | 18.13B | 15.27B | 12.90B | 11.03B | 9.99B |
Cash Flow | ||||||
| Free Cash Flow | 975.85M | 1.36B | 1.80B | 1.01B | 519.70M | -373.59M |
| Operating Cash Flow | 1.51B | 2.47B | 2.65B | 2.46B | 2.07B | 1.67B |
| Investing Cash Flow | -212.84M | -1.63B | -1.55B | -1.58B | -1.12B | -1.95B |
| Financing Cash Flow | -1.13B | -986.67M | -992.15M | -852.19M | -1.00B | 311.24M |
Concord Biotech Ltd. Technical Analysis
Positive
1338.60
Price Trends
1133.14
Negative
1240.34
Negative
1445.53
Negative
Market Momentum
-26.17
Negative
49.64
Neutral
55.86
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IN:CONCORDBIO, the sentiment is Positive. The current price of 1338.6 is above the 20-day moving average (MA) of 1054.41, above the 50-day MA of 1133.14, and below the 200-day MA of 1445.53, indicating a neutral trend. The MACD of -26.17 indicates Negative momentum. The RSI at 49.64 is Neutral, neither overbought nor oversold. The STOCH value of 55.86 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for IN:CONCORDBIO.
Concord Biotech Ltd. Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
68 Neutral | ₹69.98B | 57.24 | ― | 0.22% | 20.56% | 25.05% | |
66 Neutral | ₹106.27B | 54.58 | ― | 0.80% | 6.38% | -4.22% | |
63 Neutral | ₹566.20B | 91.56 | ― | 0.12% | 13.99% | -27.80% | |
61 Neutral | ₹117.65B | 59.25 | ― | 0.74% | 1.43% | 29.21% | |
61 Neutral | ₹169.72B | 439.86 | ― | 0.19% | 5.05% | -29.81% | |
55 Neutral | ₹219.92B | -41.77 | ― | 0.08% | -0.87% | -522.01% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
* Healthcare Sector Average
IN:CONCORDBIO
Concord Biotech Ltd.
1,057.45
-483.59
-31.38%
IN:BIOCON
Biocon Limited
361.80
41.58
12.98%
IN:BLUEJET
Blue Jet Healthcare Limited
443.75
-266.25
-37.50%
IN:JUBLINGREA
Jubilant Ingrevia Ltd.
734.60
64.10
9.56%
IN:PPLPHARMA
Piramal Pharma Limited
168.75
-46.06
-21.44%
IN:SYNGENE
Syngene International Ltd.
437.90
-177.76
-28.87%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.